INTRODUCTION
In an earlier article I described the context and process of the Obama Administration's "Meaningful Use" ("MU"), the touchstone by which healthcare providers would qualify for stimulus funds made available by the Health Information Technology for Economic and Clinical Health Act ("HITECH"). ' Despite President Bush's commitment in 2004 to adopting a national Electronic Health Records system, by 2009 only seventeen percent of U.S. doctors and ten percent of hospitals had even basic Electronic Medical Record ("EMR") systems. Moreover, fewer than two percent of U.S. hospitals had comprehensive systems.
While the most frequently cited reason for Health Information Technology's ("HIT") low adoption rate has been high cost, the far more nuanced barrier has been market failure, even multiple market failures. Much of the savings from EMR accrue to payers, such as health insurers, rather than the health care providers actually investing in the technology. As a result, it has been difficult to make the Return on Investment ("ROI") business case for the adoption of EMR products.
This article begins by briefly restating the concepts behind the "meaningful use of certified EMR technology" and the types of requirements included in the MU stage 1 regulation of 2010. Second, the article provides additional context for the design of stages 2 and 3, noting, for example, the impact of more general healthcare reform and some studies that have been critical of the MU strategy. Third, the article briefly explains the processes behind the development of stage 2 and the criticisms leveled at early drafts. Finally, with Department of Health and Human Services
The stage 1 regulation was published in July 20102 and established a two-tier, core/menu model. This core/menu approach rotated around a set of fifteen "core objectives" that eligible providers and hospitals must satisfy to qualify for EMR funding and a "menu set" of ten objectives (twelve for professionals) from which five must be chosen and fulfilled. Each group of objectives includes a series of core (or mandatory) criteria and a series of menu criteria. Each criterion is accompanied by an outcome. For example, the fifteen objectives in the EP core set include the use of computerized physician order entry ("CPOE") for medication orders and the documentation of the smoking status of patients thirteen years old or older. The menu set includes objectives such as incorporating clinical lab test results into the record as structured data and providing patients with timely electronic access to their health information.
The stage 1 final rule is considerably less rigorous than the proposed rule that had foreshadowed it. Industry pushback and Congressional criticism led CMS/ONC to reduce provider eligibility objectives by introducing the core set/menu set distinction and to reduce the outcome measures.
While the MU rule applies to providers who wish to benefit from stimulus funding, the Certification rule applies to the technology those providers will actually use.
3 Before "meaningful use of certified EMR technology" could become operational, regulators had to address the certified question. This involved two issues: the issuance of the certification standards themselves and a method of recognizing organizations that would apply those standards to proffered records technologies (i.e., actually certify EMR products).
The certification standards rule provides for the minimum specifications necessary to build and have certified an EMR system. Such specifications include the ability to record and chart vital signs, the maintenance of active medication lists, the maintenance of medication allergy lists, the ability to include laboratory test results, and the capability to generate lists of patients with specific conditions. As to who would perform the certification, a temporary program was implemented that is due to expire at the end of 201 1.
4 A Permanent Certification Program regulation was published in January 2011.5 The National Coordinator will use the permanent program to authorize organizations to certify EMR technology, such as Complete EMRs and/or EMR Modules. The transition from the temporary to permanent programs likely will occur in late 2011 or early 2012. The National Institute of Standards and Technology ("NIST") will accredit testing organizations and develop test tools and procedures. Every three years ONC will appoint an ONC-approved accreditor ("ONC-AA"), and that body will accredit other organizations (ONC-Authorized Certification Bodies or "ONC-ACBs" that replace the ONC-ATCBs under the temporary program) to actually accredit the technologies. CMS/ONC faced some difficult hurdles with involving industry players in the MU process. Healthcare providers had lagged behind the HIT curve and, while keen to have the government fund a proportion of their HIT upgrade costs, had not planned or budgeted for major change. Furthermore, the EMR industry was composed of hundreds of vendors, few of which were known for nimbleness or innovation. Consistent with its "escalator" model 7 CMS/ONC hoped that the concessions it made between the stage 1 proposed and final rules would maximize participation and that the agencies could ramp up the MU criteria for the later stages.
No doubt a period of relative stability and steady progression in the promulgation of stage 1 of MU would have helped this process. In fact, stage I was followed by a period of considerable disruption. First, the leadership of the project was to undergo significant changes. Second, MU and HIT found themselves being embroiled in the broader Healthcare Reform of the Patient Protection and Affordable Care Act (Affordable Care Act, or "ACA"), particularly with regard to Accountable Care Organizations ("ACOs"). Third, issues have arisen as to the soundness of the federal government's approach to EMRs, data and interconnectivity, prompting broader questions about how best to stimulate innovation in the EMR space. ways, this era began more than a year earlier, with the passage of ...
A. Leadership Change and Other Challenges
[HITECH]."l2 Obviously there are some thematic relationships between the two pieces of legislation. Indeed, Dr. Blumenthal and his HHS colleagues promoted the synergy between their HIT work and ACA's goals of improving quality, reducing costs, and accelerating outcomes research.
In today's somewhat darker days for healthcare reform, that linkage between HITECH and ACA may be harder to navigate. The poster child for linkage is the proposed ACO regulation.
3 Officially, as laboratories for future healthcare models, ACOs are expected to innovate through their adoption of HIT ("It will draw upon the best, most advanced models of care, using modem technologies, including telehealth and electronic health records, and other tools to continually reinvent care in the modem age" 4 ).
As originally conceptualized ACOs would require (maybe even revolve around) robust HIT systems in order to integrate the data flow between the participants and to provide outcomes reporting. Future ONC Coordinator Mostashari commented on the draft regulation as follows: "Health IT tools are an essential foundation to support the kinds of coordinated, patientcentered, and accountable care envisioned by the ACO program," and noted that the overlap between the clinical quality measures used in the MU program and the proposed ACO rule "strongly signals a desire for even greater alignment of the reporting requirements for ACOs and MU, including through eventual reporting of clinical quality measures directly from EHRs."' 5 Thus, HIT requirements and synchronization with MU pervaded the ACO proposed regulation. For example, the meaningfully used EMR was to be the favored method for collecting outcomes and other data from ACO participants, and another requirement demanded that "at least 50 percent of an ACO's primary care physicians must be meaningful EMR users, using certified EMR technology... ." 16 However, as the wheels threatened to come off the ACO proposal, 7 some of the criticisms targeted the HIT proposals.' 8 More formally, the AMA called the fifty percent rule "premature" and "strongly recommend [ed] that ACOs should have the flexibility to come up with their own percentage requirements for meeting EHR meaningful use measures." 9 Regarding a different provision allowing beneficiaries who see an ACO PCP to opt-out of having their claims data shared, 2 o the College of Healthcare Information Management Executives ("CHIME") retorted, "If beneficiary claims data are withheld, the ACO's ability to improve individual beneficiary health, as well as achieve the desired shared savings, could be compromised." 2 In the final regulations announced by CMS in late 201122 the linkages between ACOs and MU were noticeably reduced. In particular the 50 percent meaningful user requirement was dropped. The final rule also dramatically reduced the number of quality measures that have to be reported. 23 Parallels between ACOs and MU are readily identified. For example, the core regulatory structures are built around similar matrices. Less positively, as one commentator observed, both fall on the government sword of "underestimat[ing] the costs associated with projects it champions, while at the same time overestimating savings." 2 4 And, in both cases the industry is looking for the pot to be sweetened. If the ACO proposal fails or becomes sweetened to the extent industry desires, then the linkage drawn between HITECH and ACA may be regretted. 
C. EMR Qualms, PCAST and Interconnectivity
Historically, the contentious component of the history of EMRs has been funding, not their ability to dramatically improve health care. Accordingly, the primary research findings publication in early 2011 stated there was "no association between EHR use and care quality for nineteen indicators and a positive relationship for only one indicator." 25 In response, ONC staff published a literature review in Health Affairs in March 2011 that suggested a far more positive correlation of HIT to improved patient safety. 26 There was better news out of HIT's bellwether state. According to a 2011 report by the California HealthCare Foundation, physician practices with an EMR in place sharply increased to forty-eight percent. In addition, the gains and penetration in larger practices for EMRs and for most forms of HIT, such as CPOE, e-prescribing, and decision support were notable. Where PCAST was insightful (and clearly differed from the CMS/ONC approach) was in viewing data exchange as a major priority (for patient care, health research, and to create network value and so stimulate adoption) and in its skepticism for useful data exchange emerging from the current generation of EMRs, even when supported by Health Information Exchanges ("HIE"). 
Anticipating Stage Two
While the CMS/ONC approach has been to concentrate on EMRs (requiring certification) and users (requiring MU), PCAST concentrated on less aggregated data. Specifically, its focus is less on a patient's medical record (containing all the data elements from a single provider) and more on the discrete data elements surrounding a patient from all providers. To be useful PCAST believes those data elements must be in a universal exchange language (likely an XML variant). This markup language would provide the metadata that provides patient identifying information, privacy protocols, and provenance relating to that data element. The other piece of the puzzle for PCAST was how to search for and collate these data elements. For PCAST the answer is data-element access services ("DEAS") -specialized and secured search engines that would crawl the meta-data and be able to respond to searches by patients or providers.
The critical regulatory pieces for PCAST therefore were that CMS/ONC should define a mark up language and require its use as part of the future MU stages, "define standards for the surfacing of metadata for use by the data element access services," and support the growth of DEAS. Although PCAST did not use this language, there was a distinct impression that the authors of PCAST believed that the stimulus money was being used to replace paper records silos with electronic ones.
29
PCAST was fundamentally flawed, particularly in the way it approached privacy and security. 30 It was quickly rejected by the EMR industry that preferred a document-centric approach and described the PCAST proposal "to manage clinical data and security at the individual data element level" as "unworkable." 3 1 By March 2011, the HIT Committee's PCAST workgroup and then the HIT Committee itself had rejected the PCAST proposals as based on untested theoretical models with enormous and unsolved privacy and operational issues. 32 Notwithstanding, ONC must have seen some validity in the PCAST proposals, or at least appreciated the political power of its source. In August 2011 the agency published an advanced NPRM for metadata standards albeit for summary care records.
In early 2011, a report from PricewaterhouseCoopers ("PwC") complemented the PCAST critique. A key finding of "Putting patients into 'Meaningful Use"' 34 was that "[t]o achieve the ultimate goal of patientcentered care" providers "need patients to buy into the concept and utilize the health IT tools supporting it. The implication of not involving patients early in the process might be lower and slower adoption and utilization of these tools." 35 The report speculated that health systems had delayed work on their patient portals to deal with other MU requirements and noted that the MU criteria fail to measure patient engagement. To an extent, the PwC report looks at the PCAST lack of market innovation from the patient demand side. There are many reasons to be skeptical about personal health records.
3 6 However, it does seem to be a reasonable argument that innovation and competition in the EMR space will happen only with a major increase in patient involvement and demand.
The disruption served by the developments outlined above was not fatal to the HITECH-mandated process. Yet, together the developments suggested that the CMS/ONC model had flaws and invited provider skepticism about the agencies' vision of stages 2 and 3.
IV. PREVIEWING STAGES 2 AND 3
As a result, rather than tamping down the anxiety (and lack of preparation) of potential recipients of HITECH largesse by providing a gentle ramp up in stage 1, the debate over the level of MU merely started all over again. we've asked of them," yet at the same time not to allow the escalator "to turn into one of those airport moving walkways where you end up after a long trip at precisely the same altitude as where you started." In August 2011,42 CMS announced that 77,000 providers had registered for incentive payments and the Medicare and Medicaid programs had paid out $400 million.
A. The Escalator Problem
According to a 2011 Fitch Ratings report, not-for-profit hospitals that have implemented advanced HIT enjoyed higher profits and profit growth rates. 43 Further, a 2010 McKinsey report estimated that, at least for hospitals, HIT investment could return its investment. 4 Notwithstanding, the PwC survey discussed above 45 suggested that fewer HITECH subsidy participants would achieve MU (down to 82 percent compared to 90 percent this time last year). In part, this scenario may have been exacerbated by the transition from ICD-9 to ICD-10 4 6 and changes to diagnosis and procedure 
B. Process and Pushback
When the MU roadmap was published, three discrete stages were anticipated. Stage 2 criteria were to be published in late 2011 and stage 3 criteria to appear in late 2013. At the time that stage 1 was announced, it was thought that stages 2 and 3 would demand a more robust health information exchange (including orders and test results) and the ability of the data to better "follow" the patient. It was assumed that stage 2 would expand stage 1 criteria to encompass care delivery standards in the areas of disease management, clinical decision support, medication management, patient access to their own health information, transitions in care, quality measurement and research, and bi-directional communication with public health agencies. Subsequently, stage 3 would focus on decision support, self-management tools for patients, and improving population health outcomes.
A notice of proposed rulemaking ("NPRM") for stages 2 and 3 is expected in the first quarter of 2012 and as before is being spearheaded by the Meaningful Use Workgroup of the HIT Policy Committee ("HITPC"). 49 The Workgroup included a spreadsheet of the proposed stage 2 and 3 Objectives and Measures in November 20 10,50 and then presented its recommendations to the HITPC in December," after which HITPC opened up its recommendations for public comment in January 201 1. 52 Perhaps there was no surprise when the patterns of action and argument from stage I started to reappear. Healthcare and HIT industries, physicians, and Congress began to cast doubts on the adequacy of funding for the initiative and sought to pressure CMS/ONC to make only modest upward changes in MU and/or delay stage 2.
The basic arguments can be discerned from some of the more than 400 comments sent to the HITPC regarding stage 2. For example, the American Hospital Association noted " In contrast, 25 consumer advocacy organizations, led by National Partnership for Women & Families and including AARP, the AFL-CIO, and Consumers Union, filed a very positive comment approving of the movement of menu objectives to core, the use of evidence as key to decision support, the incorporation of advance directive information, and of general patient interaction.
At Congressional hearings held in June 2011 some in industry took the position that MU is dominated by compliance and so industry energies are aimed at compliance rather than innovation.ss Testifying, the CEO of a well-known HIT company stated:
Whether Meaningful Use standards are right or wrong is not the real issue. What is important is that today, the end-users, doctors and patients, are further away than ever from system design, because new product development is focused on satisfying those regulatory hurdles, rather than on simple innovations that improve productivity. As a result, program requirements are disruptive to the processes in place in increasingly busy offices.
A dermatologist testifying before the same panel argued that "there are significant barriers to full-scale adoption and implementation of HITspecifically, cost, regulatory barriers, financial penalties, an unpredictable marketplace and system integration" and, specifically, doctors "investing in EHRs are struggling with the structure of the CMS Meaningful Use timeline." 6 o By May 2011, HITPC was discussing some more conservative options and at its June 8, meeting accepted the recommendations of the MU Workgroup that stage 2 be delayed by one year. 61 If the HITPC draft is accepted by CMS/ONC, a notice of proposed rulemaking should be published in late 2011. The areas of criticism have already been flagged by industry players and no doubt will be vociferously re-argued during the NPRM process. The question will be whether CMS/ONC, having conceded the timing issue for 2011 attesters, holds firm on the rest of stage 2. Looking forward, 2015's Stage 3 is likely to include provisions relating to telehealth (particularly for in-home monitoring), ethnographic research, and additional patient-generated data such as survey and self-monitoring data.
V.
ASSESSING PROGRESS It is important to recall the immensity of the task that HITECH assigned to these three sets of players (regulators, HIT vendors, and healthcare providers). To merely distribute such a large amount of government funding in the MU timeframe would be a considerable undertaking. To do so following the statutory criteria and on a timeline designed to have rapid economic impact while simultaneously educating two major industries on the future of HIT is a monumental task. Steve Lohr has described it as a "grand experiment" and a "huge challenge in innovation design." 63 This experiment does not operate in a vacuum. Existing programs such as e-prescribing6' or new ones such as ACOs need to be integrated. Finally, ONC is working with nothing resembling a clean sheet of paper: it does not control records technologies, such as their disparate interfaces, 65 merely some of their expected functions.
Excuses and obstacles aside, the core question remains: whether HITECH and its MU touchstone will transcend stimulus fund status as a public works project and transform US healthcare? In a blog post as he was departing ONC, Dr. Blumenthal lauded the adoption numbers the stimulus program had achieved:
In the last two years, however, there has been a significant upward inflection in the adoption rate. For primary care providers, adoption of a basic EHR increased by half from 19.8 percent in 2008 to 29.6 percent in 2010. And with HITECH Act programs now in full swing, it looks clear that adoption and use of health information technology will go into high gear. Already, 81 percent of hospitals and 41 percent of office physicians are saying they intend to achieve meaningful use of EHRs and qualify for Medicare and Medicaid incentive payments.66
Those and other 67 figures supply an excellent answer but not necessarily to the correct question. Spending $27 billion to buy EMR systems is always going to increase EMR adoption. Indeed, a 2011 survey found that the strongest driver for EMR implementation continued to be the MU incentives rather than any endogenous features. 68 The far more difficult questions are whether that adoption of EMRs will be transformational; whether providers will continue to use, update, and replace EMR systems when the stimulus money is gone; and whether investment and innovation will continue? Will the less visible state-based HIE proposals find traction?
It is highly unlikely that there will be a single answer to any of these questions because the MU-regulated expenditures likely will have disparate impacts on different groups of providers. The trend of extracting high value
